UB Paderborn / Katalog / Suche / in CDI

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

The lancet oncology, 2012, Vol.13 (1), p.25-32

2012

Volltextzugriff (PDF)

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Journal of clinical oncology, 2012-05, Vol.30 (14), p.1594-1600

2012

Volltextzugriff (PDF)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Breast cancer research : BCR, 2017-02, Vol.19 (1), p.16-16, Article 16

2017

Volltextzugriff (PDF)

Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca²⁺ release and apoptosis

Proceedings of the National Academy of Sciences - PNAS, 2008-02, Vol.105 (7), p.2427-2432

2008

Volltextzugriff (PDF)

Pertuzumab, Trastuzumab and Chemotherapy in Her2-Positive Metastatic Gastric or Gastro-Oesophageal Junction Cancer: an International Phase III Study (Jacob)

Annals of oncology, 2013-06, Vol.24, p.iv67-iv67

2013

Volltextzugriff (PDF)

Improving ethnic and racial diversity within clinical trial populations through community recruitment and inclusion initiatives: Experience from MyTACTIC

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.e13679-e13679

2024

Volltextzugriff (PDF)

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes

The oncologist (Dayton, Ohio), 2024-06, Vol.29 (6), p.534-542

2024

Volltextzugriff (PDF)

Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6507-6507

2023

Volltextzugriff (PDF)

A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS1588-TPS1588

2021

Volltextzugriff (PDF)

MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors

Journal of clinical oncology, 2024-01, Vol.42 (3), p.258-265

2024

Volltextzugriff (PDF)

Evolution of biomarker testing in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC) in U.S. community practices

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18778-e18778

2022

Volltextzugriff (PDF)

Biomarker testing patterns and actionability in advanced non-small cell lung cancer (aNSCLC) at OneOncology (OneOnc)

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.287-287

2021

Volltextzugriff (PDF)

NGS testing patterns in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC): OneOncology (OO) sites compared to Flatiron Health Nationwide (NAT)

Journal of clinical oncology, 2021-10, Vol.39 (28_suppl), p.288-288

2021

Volltextzugriff (PDF)

Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA

Future oncology (London, England), 2023-06, Vol.19 (20), p.1397-1414

2023

Volltextzugriff (PDF)

Abstract OT3-1-01: A two-cohort, phase II, cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory, or early breast cancer

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.OT3-1-01-OT3-1-01

2015

Volltextzugriff (PDF)

Abstract CT128: A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC)

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT128-CT128

2022

Volltextzugriff (PDF)

Abstract 1209: Tumor informed circulating tumor DNA monitoring for early treatment response and survival outcomes on trastuzumab + pertuzumab

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1209-1209

2024

Volltextzugriff (PDF)

MotHER: A registry for women with breast cancer who received trastuzumab (T) with or without pertuzumab (P) during pregnancy or within 6 months prior to conception

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS658-TPS658

2013

Volltextzugriff (PDF)

Abstract CT032: Activity and safety of alectinib for ALK-altered solid tumors from MyPathway

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT032-CT032

2022

Volltextzugriff (PDF)

Abstract 2267: Biomarker testing and treatment (tx) patterns in a large community oncology network

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.2267-2267

2022

Volltextzugriff (PDF)

Pertuzumab Pharmacokinetics and Safety in Combination with Trastuzumab and Chemotherapy in Patients with Her2-Positive Advanced Gastric Cancer (Agc)

Annals of oncology, 2013-06, Vol.24, p.iv19-iv19

2013

Volltextzugriff (PDF)

Augmented Contractile Response of Vascular Smooth Muscle in a Diabetic Mouse Model

Journal of vascular research, 2003-11, Vol.40 (6), p.520-530

2003

Volltextzugriff (PDF)

Agonist‐induced mitochondrial Ca2+ transients in smooth muscle

The FASEB journal, 2003-01, Vol.17 (1), p.28-37

2003

Volltextzugriff (PDF)

Basal calcium entry in vascular smooth muscle

European journal of pharmacology, 2004-11, Vol.505 (1), p.19-29

2004

Volltextzugriff (PDF)

Sequential opening of IP3-sensitive Ca2+ channels and SOC during alpha -adrenergic activation of rabbit vena cava

American journal of physiology. Heart and circulatory physiology, 2002-05, Vol.282 (5), p.H1768

2002

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca²⁺ release and apoptosis

Pertuzumab, Trastuzumab and Chemotherapy in Her2-Positive Metastatic Gastric or Gastro-Oesophageal Junction Cancer: an International Phase III Study (Jacob)

Improving ethnic and racial diversity within clinical trial populations through community recruitment and inclusion initiatives: Experience from MyTACTIC

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes

Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO)

A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC)

MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors

Evolution of biomarker testing in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC) in U.S. community practices

Biomarker testing patterns and actionability in advanced non-small cell lung cancer (aNSCLC) at OneOncology (OneOnc)

NGS testing patterns in advanced non-small cell lung cancer (aNSCLC) and metastatic breast cancer (mBC): OneOncology (OO) sites compared to Flatiron Health Nationwide (NAT)

Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA

Abstract OT3-1-01: A two-cohort, phase II, cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory, or early breast cancer

Abstract CT128: A study evaluating targeted therapies in participants who have advanced solid tumors with genomic alterations or protein expression patterns predictive of response (MyTACTIC)

Abstract 1209: Tumor informed circulating tumor DNA monitoring for early treatment response and survival outcomes on trastuzumab + pertuzumab

MotHER: A registry for women with breast cancer who received trastuzumab (T) with or without pertuzumab (P) during pregnancy or within 6 months prior to conception

Abstract CT032: Activity and safety of alectinib for ALK-altered solid tumors from MyPathway

Abstract 2267: Biomarker testing and treatment (tx) patterns in a large community oncology network

Pertuzumab Pharmacokinetics and Safety in Combination with Trastuzumab and Chemotherapy in Patients with Her2-Positive Advanced Gastric Cancer (Agc)

Augmented Contractile Response of Vascular Smooth Muscle in a Diabetic Mouse Model

Agonist‐induced mitochondrial Ca2+ transients in smooth muscle

Basal calcium entry in vascular smooth muscle

Sequential opening of IP3-sensitive Ca2+ channels and SOC during alpha -adrenergic activation of rabbit vena cava

Suchergebnisse filtern